Immunohistochemical studies on variation of ER, PR and Her-2 in breast DCIS, DCIS with microinvasive and invasive ductal carcinoma

Objective　To analyze the variations of ER, PR and HER-2 in breast ductal carcinoma in situ (DCIS), DCIS with micro-invasive (DCIS-Mi), and invasive ductal carcinoma (IDC) to establish a basis for further study on DCIS-Mi. Methods　 The samples of 30 DCIS, 51 DCIS-Mi and 49 IDC diagnosed by pathology from patients hospitalized in 307 hospital of PLA from October 2002 to February 2013, were collected in the present study. The expressions of ER, PR and Her-2 in breast DCIS, DCISMi and IDC were determined by immunohistochemical staining method. Results　When ≥10% tumor nuclei were colored, it was judged as positive, the expressions of ER in DCIS, DCIS-Mi and IDC were found to be 63.33%, 41.18% and 79.59% (P<0.001), and of PR were 53.33%, 37.25% and 61.22% (P=0.052). Judged to be positive when ≥1% tumor nuclei were colored, the expressions of ER in DCIS, DCIS-Mi and IDC were found to be 66.67%, 52.94% and 83.67% (P<0.01), and of PR were 66.67%, 47.06% and 75.51% (P=0.012). The expressions of Her-2 in DCIS, IDC and DCIS-Mi were 26.67%, 27.45% and 18.37% respectively (P=0.012). The expressions of ER in DCIS classⅠand Ⅱ were higher than that in class Ⅲ, the expression of PR in DCIS class Ⅰ was higher than that in class Ⅱ and Ⅲ, and the expressions of Her-2 in DCIS classⅠand Ⅱ were lower than that in class Ⅲ (P<0.05). Conclusions 　There are probably different molecular biological and genetical changes in DCIS-Mi from DCIS and IDC. The expressions of ER, PR and Her-2 in DCIS are closely correlated with the histological grading, and the differences may be related to different genetic expressions in different stages of breast cancer development. DOI: 10.11855/j.issn.0577-7402.2014.09.04